80680b8f-eec8-4b02-95c4-f133af61943a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.390
- G2M_CHECKPOINT+0.250
- E2F_TARGETS+0.190
- MITOTIC_SPINDLE+0.170
- BILE_ACID_METABOLISM+0.150
- SPERMATOGENESIS+0.140
- MYC_TARGETS_V2+0.120
- MYC_TARGETS_V1+0.050
- DNA_REPAIR+0.030
- XENOBIOTIC_METABOLISM+0.030
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- TNFA_SIGNALING_VIA_NFKB-0.600
- ANGIOGENESIS-0.590
- ALLOGRAFT_REJECTION-0.580
- INFLAMMATORY_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.510
- COMPLEMENT-0.490
- IL6_JAK_STAT3_SIGNALING-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- IL2_STAT5_SIGNALING-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ERWT0ZWE | medulloblastoma | — | 0.918 |
| 2 | BS_9M5XJ10G | medulloblastoma | — | 0.916 |
| 3 | TCGA-55-8620-01A-11R-2403-07 | — | cohortA3 | 0.913 |
| 4 | BS_61E80SD6 | medulloblastoma | — | 0.912 |
| 5 | SRR12202497 | — | — | 0.902 |
| 6 | BS_BA6AZWB3 | medulloblastoma | — | 0.902 |
| 7 | BS_2SFTWNVE | medulloblastoma | — | 0.900 |
| 8 | SRR13780269 | — | cohortSC | 0.900 |
| 9 | SAMN03290891 | — | — | 0.900 |
| 10 | SRR8518343 | — | E | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |